Literature DB >> 20606418

Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: Role of STAT1 inhibition and nephrin restoration.

Sydney C W Tang1, Joseph C K Leung, Loretta Y Y Chan, Amy Shan Cheng, Hui Yao Lan, Kar Neng Lai.   

Abstract

BACKGROUND: Rosiglitazone (Ros) has been shown to attenuate CXCL8 and ICAM-1 overexpression in renal tubular cells exposed to glycated albumin. The present study explores whether this can be translated into renoprotection in vivo. Uninephrectomized (Unx) type 2 diabetic db/db mice were chosen as a model of accelerated diabetic nephropathy.
METHODS: Uninephrectomy was performed in 10-week-old db/db mice. They were then treated with vehicle, metformin or Ros for 8 weeks.
RESULTS: Unx-db/db mice treated with Ros had lower serum creatinine and albuminuria, less severe glomerulosclerosis, tubulointerstitial injury, fewer infiltrating macrophages, and less proliferating nuclear antigen-positive tubular cells compared with mice treated with metformin that had a similar level of glycemic control and insulin resistance. In addition, Ros but not metformin attenuated renal cortical expression of CCL2, MIP-2, and ICAM-1 and inhibited p-STAT1 signal activation. Ros also increased glomerular nephrin expression.
CONCLUSIONS: Our results delineated the biochemical and histologic characteristics of Unx-db/db mice and demonstrated the in vivo glucose-independent anti-inflammatory mechanisms of Ros in nephropathy of accelerated murine type 2 diabetes. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20606418     DOI: 10.1159/000316056

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

1.  Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.

Authors:  Kar Neng Lai; Loretta Y Y Chan; Hong Guo; Sydney C W Tang; Joseph C K Leung
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

2.  Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy.

Authors:  Miao Lin; Wai Han Yiu; Hao Jia Wu; Loretta Y Y Chan; Joseph C K Leung; Wo Shing Au; Kwok Wah Chan; Kar Neng Lai; Sydney C W Tang
Journal:  J Am Soc Nephrol       Date:  2011-10-21       Impact factor: 10.121

3.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

4.  Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions.

Authors:  Sebastian Langer; Reinhold Kreutz; Andreas Eisenreich
Journal:  J Nephrol       Date:  2016-01-05       Impact factor: 3.902

Review 5.  The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases.

Authors:  Jianjun Gao; Zhaoyan Gu
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

Review 6.  New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors.

Authors:  Prabhakar Busa; Yaswanth Kuthati; Niancih Huang; Chih-Shung Wong
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

7.  The CPLANE protein Intu protects kidneys from ischemia-reperfusion injury by targeting STAT1 for degradation.

Authors:  Shixuan Wang; Aimin Liu; Guangyu Wu; Han-Fei Ding; Shuang Huang; Stanley Nahman; Zheng Dong
Journal:  Nat Commun       Date:  2018-03-26       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.